Key result
In patients with pulmonary artery hypertension, good responders to chronic epoprostenol therapy showed a greater reduction in mean pulmonary artery pressure compared to poor responders.
Why the study?
Does an increase in cardiac output precede lowering of pulmonary artery pressure during chronic epoprostenol therapy in patients with pulmonary artery hypertension?
Cohort (n=32)
Yes
Does an increase in cardiac output precede lowering of pulmonary artery pressure during chronic epoprostenol therapy in patients with pulmonary artery hypertension?
In patients with pulmonary artery hypertension, chronic epoprostenol therapy leads to continued hemodynamic improvements even after reaching an optimal fixed dose, though an increase in cardiac output does not necessarily precede the lowering of pulmonary artery pressure.
Answers are grounded in this paper and cite their sources.
Responder classification may predict larger mPAP reductions with epoprostenol; leaves open mechanisms and prospective utility.
BACKGROUND: Sequential changes in the hemodynamic effect of chronic epoprostenol therapy raise the following questions. Does an increase in cardiac output (CO) precede lowering of the pulmonary artery pressure (PAP) over the time course of improvement? What are the characteristics of good responders to chronic epoprostenol treatment? METHODS AND RESULTS: Hemodynamics were evaluated by catheter examination. Most patients still alive after >1 year showed an increase in CO either with no change in mean PAP or accompanied by a decrease in mean PAP during increased dosing of epoprostenol. Immediately before cessation of the increase in epoprostenol dose in good responders, the ratio of total pulmonary resistance to total systemic resistance was low, and the pulmonary artery wedge pressure minus right atrial pressure was high compared with the newest data in poor responders. One year after fixing at the best dose of epoprostenol, the mean PAP further decreased. CONCLUSIONS: In good responders, pulmonary selectivity to epoprostenol is high, and the blood returning to the left-sided heart through the pulmonary circulation increases. Hemodynamics further improve, even after fixing at the best dose of epoprostenol. The present data did not show that an increase in CO precedes lowering of the PAP over the course of improvement.
No takes yet. Share an insight, caveat, or question.
Sakuma et al. (2009) conducted a cohort in Pulmonary Artery Hypertension (n=32). Epoprostenol vs. Poor responders (Group A) was evaluated on Percentage change in mean pulmonary artery pressure (PAP) from baseline (p=0.001). In patients with pulmonary artery hypertension, good responders to chronic epoprostenol therapy showed a greater reduction in mean pulmonary artery pressure compared to poor responders.
Synapse has enriched 10 related papers. Consider them for comparative context: